Kester MI - Search Results

1

Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort.

Schoonenboom NS, Reesink FE, Verwey NA, Kester MI, Teunissen CE, van de Ven PM, Pijnenburg YA, Blankenstein MA, Rozemuller AJ, Scheltens P, van der Flier WM. Schoonenboom NS, et al. Among authors: kester mi. Neurology. 2012 Jan 3;78(1):47-54. doi: 10.1212/WNL.0b013e31823ed0f0. Epub 2011 Dec 14. Neurology. 2012. PMID: 22170879

2

Evaluation of plasma Abeta40 and Abeta42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment.

Kester MI, Verwey NA, van Elk EJ, Scheltens P, Blankenstein MA. Kester MI, et al. Neurobiol Aging. 2010 Apr;31(4):539-40; author reply 541. doi: 10.1016/j.neurobiolaging.2008.07.024. Epub 2008 Oct 28. Neurobiol Aging. 2010. PMID: 18963255 No abstract available.

3

CSF biomarkers in Alzheimer's disease and controls: associations with APOE genotype are modified by age.

Kester MI, Blankenstein MA, Bouwman FH, van Elk EJ, Scheltens P, van der Flier WM. Kester MI, et al. J Alzheimers Dis. 2009;16(3):601-7. doi: 10.3233/JAD-2009-0999. J Alzheimers Dis. 2009. PMID: 19276554

4

Dementia: the bare essentials.

Kester MI, Scheltens P. Kester MI, et al. Pract Neurol. 2009 Aug;9(4):241-51. doi: 10.1136/jnnp.2009.182477. Pract Neurol. 2009. PMID: 19608778 Review. No abstract available.

5

Progression from MCI to AD: predictive value of CSF Aβ42 is modified by APOE genotype.

Kester MI, Verwey NA, van Elk EJ, Blankenstein MA, Scheltens P, van der Flier WM. Kester MI, et al. Neurobiol Aging. 2011 Aug;32(8):1372-8. doi: 10.1016/j.neurobiolaging.2009.08.006. Epub 2009 Sep 11. Neurobiol Aging. 2011. PMID: 19748159

6

Patients with Alzheimer disease with multiple microbleeds: relation with cerebrospinal fluid biomarkers and cognition.

Goos JD, Kester MI, Barkhof F, Klein M, Blankenstein MA, Scheltens P, van der Flier WM. Goos JD, et al. Among authors: kester mi. Stroke. 2009 Nov;40(11):3455-60. doi: 10.1161/STROKEAHA.109.558197. Epub 2009 Sep 17. Stroke. 2009. PMID: 19762705

7

CSF biomarkers predict rate of cognitive decline in Alzheimer disease.

Kester MI, van der Vlies AE, Blankenstein MA, Pijnenburg YA, van Elk EJ, Scheltens P, van der Flier WM. Kester MI, et al. Neurology. 2009 Oct 27;73(17):1353-8. doi: 10.1212/WNL.0b013e3181bd8271. Neurology. 2009. PMID: 19858456

8

Additional value of CSF amyloid-beta 40 levels in the differentiation between FTLD and control subjects.

Verwey NA, Kester MI, van der Flier WM, Veerhuis R, Berkhof H, Twaalfhoven H, Blankenstein MA, Scheltens And P, Pijnenburg YA. Verwey NA, et al. Among authors: kester mi. J Alzheimers Dis. 2010;20(2):445-52. doi: 10.3233/JAD-2010-1392. J Alzheimers Dis. 2010. PMID: 20164558

9

Joint effect of hypertension and APOE genotype on CSF biomarkers for Alzheimer's disease.

Kester MI, van der Flier WM, Mandic G, Blankenstein MA, Scheltens P, Muller M. Kester MI, et al. J Alzheimers Dis. 2010;20(4):1083-90. doi: 10.3233/JAD-2010-091198. J Alzheimers Dis. 2010. PMID: 20413898

10

Diagnostic impact of CSF biomarkers in a local hospital memory clinic.

Kester MI, Boelaarts L, Bouwman FH, Vogels RL, Groot ER, van Elk EJ, Blankenstein MA, van der Flier WM, Scheltens P. Kester MI, et al. Dement Geriatr Cogn Disord. 2010;29(6):491-7. doi: 10.1159/000313534. Epub 2010 Jun 3. Dement Geriatr Cogn Disord. 2010. PMID: 20523047

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

36 results

Search Page

Filters